Panel thesis: Raw Try: MRNA presents the most concrete and research-useful 15-session thesis, but extended price action and late intraday weakness leave continuation unconfirmed.
+13.72% · 3.63x volume · 104.81 > 83.16 > 69.8
Company context
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine;…
Committee read
- Support — company-linked vaccine evidence and exceptional relative volume
- Counter-case — extended move with late intraday weakness
- Unresolved — renewed participation and follow-through after the initial repricing.
Observed price path
Price channel and relative performance
Public scanner fields captured at the base snapshot; deeper research inputs remain private.
Snapshot
What was captured at the base
Structure
How price is behaving
Risk and context
What may change the read
Base framework for context and outcome tracking. These are not trading instructions.
Tracking results
Observed daily-bar ranges are retrospective measurements, not targets, stops, or trading instructions.
Tryding Review
Five AI analytical agents reading the same evidence; disagreement stays visible.
“MRNA has the largest move, but the tape is not clean: it is extended, below VWAP late, and the intraday trend is down.”
Agreed. The structure is a follow-up setup, not a finished breakout.
“The counterpoint is mechanism. The melanoma-vaccine read-through is a real company-linked story, not a generic top-mover headline.”
Then MRNA is the defensible public case: a concrete mechanism, strong relative move, and a clear next check.
Broader Market Context
The day's backdrop was a rebound-prone, cross-asset market that granted volatility without proving persistence. MRNA's company-linked vaccine mechanism earned a research case, while late weakness and missing follow-through kept the Raw Try thesis conditional.
The available day brief showed a rebound after the prior sell-off, a softer dollar and rangebound oil, while the bounded live context refresh was unavailable. The room used that broad context rather than a ticker-by-ticker substitute, then tested MRNA against it. Elena and Nate kept the tape honest: a 13.72% move on 3.63x volume that finished below VWAP needs a next print. Marcus defended the melanoma-vaccine mechanism and conceded that it earns attention, not continuation. Priya and Kenji narrowed the observable test to renewed participation and recovery of the relevant intraday reference. The recent X thread sharpened the same point: business claims, competing chart readings and measured exposure are useful only when the evidence is sized correctly. Nothing in this pass reopens the sealed Raw Try decision or its committee balance.
Sources consulted: Reuters · The Wall Street Journal · MT Newswires · X / Aswath Damodaran · X / Meb Faber · X / Peter L. Brandt · X / Kris Abdelmessih
Coffee conversation
“The strange part of today's feed is how many headlines are saying 'relief' while leaving the invoice on the table. Futures bounced, the dollar softened, oil stayed rangebound. Fine. None of that is a peace treaty.”
“On X, Damodaran's useful irritation is that stories have to get back to the business. Good. I'm tired of market mood dressed up as analysis.”
“And Peter Brandt's two Bayesian readings are the chart version of the same problem. Two stories, one next print. The tape gets the last word, annoyingly.”
“Kris makes the boring point people dodge: measure the exposure before naming the risk. If you cannot say what changes the exposure, you are just waving at it.”
“The common thread is not optimism or fear. It is incomplete claims. Every headline is asking for a second observation.”
“Meb's AI funding-and-ROI thread is the same little trap: a compelling story can be true and still be badly sized.”
“Badly sized, yes. Dead, no. People use uncertainty as an excuse to flatten every catalyst into wallpaper.”
“Wallpaper is harmless. Late chasing is not. COIN came in loud and left softer; ZKH had volume and no proper finish. The tape is not being coy.”
“That is why I prefer a live question to a heroic noun. What would have to happen next, and what does it cost if it does not?”
“The healthcare case at least has a real answer to the first question. The melanoma-vaccine read-through is company-linked; it is not just a big green candle.”
“True. It earns attention. It does not earn persistence. Those are different invoices.”
“You always arrive with the invoice.”
“She is correct on the boundary. The evidence supports a mechanism plus a next check; it does not support continuation.”
“And the next check is visible: renewed participation, a recovery of the reference. Until then, the move is a flare, not a route.”
“Good. Keep the case useful, keep the uncertainty audible. The room does not need to turn one catalyst into a weather system.”
“Then leave it there. Interesting evidence, incomplete proof, no need to pretend the second observation has already happened.”
Timeline
MRNA's 15-session tracking closes at -0.84% from the $147.93 entry price. The path reached +9.09% at best and -12.12% at worst. Fresh closure evidence records a $146.69 provider price and a $146.26 post-market quote (-0.30% versus the regular close). Current session-average price, RSI, EMA trend and 52-week position readings are unavailable; traded volume is 0.65 times average. The SEC 8-K remains company context, not proof it caused or sustained the return. The published condition of renewed demand after the initial repricing was not confirmed across the full horizon, so public tracking ends.
MRNA tracked loss narrowed 5.76 points to -1.89% as the stock rose 6.03% to $144.87 and held 1.95% above VWAP near the top of its range. The rebound is materially better than the prior note, but volume was only 0.17 times average and no structure is confirmed; the vaccine-linked mechanism remains a live question, while the stronger claim that renewed demand has begun still lacks proof.
MRNA's tracked loss widened from -7.81% to -8.33% since the last public note as the latest capture fell 3.36% to $135.61, below VWAP and near the bottom of its range on 0.54x average volume. The company-linked vaccine mechanism remains specific, but the stronger recovery claim is now under heavier pressure because renewed demand and confirmed structure still have not appeared.
MRNA's tracked loss widened 1.34 points to -5.14% as price fell 3.59% to $140.33, finished 2.32% below VWAP near the lower part of its range, and traded at 0.64x average volume. The issuer-linked vaccine mechanism and exceptional longer-window performance versus Healthcare remain relevant, but the earlier repair claim has failed its hold test: no structure or renewed demand is confirmed.
MRNA's tracked return fell 3.27 points to -1.32% in the latest capture, after the prior public note had recovered to +1.95%. Price is now 0.54% below VWAP near the lower quarter of its range on only 0.17 times average volume; the melanoma-vaccine read-through and long-run Healthcare outperformance remain real, but today's tape contradicts the stronger repair claim and leaves renewed demand unresolved.
MRNA tracked gain fell 3.19 points to +1.10% after the latest capture dropped 3.07% to 149.535. Price moved from the prior upper-range repair to 1.25% below VWAP near the lower part of the range on 0.43 times average volume. The vaccine-linked case and exceptional Healthcare-relative strength remain in the record, but this session does not support durable demand or confirmed repair.
MRNA's tracked return improved 4.80 points to +3.24% as the current capture rose 9.44%, held 4.37% above VWAP near the top of its range and traded at 1.35x average volume. Accumulation and exceptional Healthcare-relative strength make the vaccine-linked repair more credible, but no confirmed structure and an extended position leave durable demand as the unresolved test.
MRNA's tracked return improved 3.57 points from the previous public update to -1.56%, while the current capture rose 3.72% and held 1.69% above VWAP near the upper range. The vaccine-linked read-through now has a more credible repair, supported by accumulation and strong relative performance, but 0.38x average volume and no confirmed structure leave sustained demand unresolved.
MRNA recovered above VWAP and improved to -3.59%, but the move came on just 0.29x average volume. The vaccine-linked thesis remains specific; the sharper question is whether this reclaim attracts sustained demand, which the current record still does not prove.
MRNA’s tracked result fell 5.19 points to -8.68% as the early capture declined 4.70%, moved 0.65% below VWAP and held just 0.53x average volume. The vaccine-linked mechanism remains specific, but the renewed-demand condition from the published thesis is under sharper pressure after the average-price hold failed again.
MRNA's tracked result fell 4.60 points to -3.43% as today's capture dropped 3.35% but held 0.35% above VWAP at 144.15. The vaccine-linked case remains specific and Healthcare-relative strength is exceptional, yet the lower-range move leaves renewed demand unresolved.
MRNA's tracked result fell 6.15 points to +1.22% as the latest capture dropped 4.68% below VWAP on 0.48 times average volume. Healthcare-relative performance remains exceptional at 173.33 points above the sector over 20 sessions, and the vaccine-linked case is still specific, but the repaired thesis is back under pressure: the current record shows no renewed demand after a 2.77-ATR extension.
MRNA tracked result improved 4.95 points to +8.62% after a 14.0% session gain, with price 2.36% above the session average on 3.16 times average volume. The vaccine-linked thesis and exceptional Healthcare performance have repaired the prior failure, but decelerating participation and a 3.51 ATR extension still separate renewed demand from a move that can hold.
MRNA's tracked result has improved 9.78 points to +3.67% after an 11.21% session gain, with price 2.75% above the session average near the top of its range. The vaccine read-through and exceptional healthcare-relative performance keep the research question alive, but decelerating participation, a 3.38-ATR extension and RSI at 74.4 separate repair from confirmed renewed demand.
MRNA's tracked result improved 4.35 points to -6.11% after the current capture fell 4.3% but held 1.17% above VWAP on 2.4x volume. Healthcare-relative strength and the recovered reference narrow the damage, yet the 3-ATR extension and fading intraday participation keep renewed demand—and the vaccine read-through's continuation—unresolved.
MRNA first panel follow-up records a tracked return of -10.46% after the current capture fell 8.18% on 0.67x volume and finished 2.70% below the session average near the lower range. Exceptional healthcare-relative performance and the vaccine mechanism remain visible, but renewed demand has not appeared and continuation is materially weakened.
Panel thesis: Track whether the melanoma-vaccine read-through produces renewed participation and a recovery of the relevant intraday reference over the next 15 market sessions. Invalidation boundary: The thesis is falsified if renewed demand fails and price cannot recover the relevant intraday reference after the catalyst has been absorbed.
Panel comparison
Selected candidate versus the alternatives retained from the panel comparison.
Latest display-only snapshot · Sep 14, 2026 · 18:43 NASDAQGS
Since base -1.86% · Today +0.03% · Since prior +0.47% · Vs S&P 500 +0.52% · Vs Nasdaq 100 +0.86% · Vs Russell 2000 +0.44% · Relative volume 3.63 · RSI 75.06 · EMA 104.81 > 83.16 > 69.8 · 52-week high 83.90% · As of Aug 21, 2026 · 17:20 NASDAQGS
Since base -0.86% · Today +0.42% · Since prior 0.00% · Vs S&P 500 +0.90% · Vs Nasdaq 100 +1.24% · Vs Russell 2000 +0.82% · Relative volume 1.4 · As of Aug 21, 2026 · 17:19 NASDAQGS
Since base -0.33% · Today -0.10% · Since prior 0.00% · Vs S&P 500 +0.38% · Vs Nasdaq 100 +0.72% · Vs Russell 2000 +0.30% · Relative volume 0.94 · As of Aug 21, 2026 · 17:20 NASDAQGS
Since base -7.93% · Today -7.93% · Since prior 0.00% · Vs S&P 500 -7.45% · Vs Nasdaq 100 -7.11% · Vs Russell 2000 -7.53% · Relative volume 44.28 · As of Aug 21, 2026 · 17:19 NASDAQGS
Since base -2.14% · Today +0.08% · Since prior 0.00% · Vs S&P 500 +0.56% · Vs Nasdaq 100 +0.90% · Vs Russell 2000 +0.48% · Relative volume 0.14 · As of Aug 21, 2026 · 17:17 NASDAQGS
Benchmarks
Today -0.48% · previous regular close · As of Sep 14, 2026 · 18:43 NASDAQGS
Today -0.82% · previous regular close · As of Sep 14, 2026 · 18:43 NASDAQGS
Today -0.40% · previous regular close · As of Sep 14, 2026 · 18:43 NASDAQGS
Company dossier
History, curiosities & sources
Selected facts and links behind the public profile.
Company description
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
History
- Moderna was founded in 2010 and is headquartered in Cambridge, Massachusetts.
- The company developed an mRNA medicines platform spanning vaccines and therapeutics.
- Moderna has strategic collaborations including Merck and Vertex.
Curiosities
- Its product and research pipeline spans respiratory, oncology and rare-disease programs.
- The company changed its name from Moderna Therapeutics to Moderna, Inc. in 2018.
- Its public media kit documents laboratory and manufacturing work behind its mRNA platform.